nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS2—adrenal gland cancer	0.759	1	CbGaD
Thalidomide—CYP2C19—urine—adrenal gland cancer	0.00536	0.0978	CbGeAlD
Thalidomide—CYP1A2—urine—adrenal gland cancer	0.00437	0.0799	CbGeAlD
Thalidomide—CYP2C9—urine—adrenal gland cancer	0.00415	0.0758	CbGeAlD
Thalidomide—CYP2E1—urine—adrenal gland cancer	0.00393	0.0719	CbGeAlD
Thalidomide—CRBN—adrenal cortex—adrenal gland cancer	0.00353	0.0644	CbGeAlD
Thalidomide—NFKB1—gonad—adrenal gland cancer	0.00348	0.0636	CbGeAlD
Thalidomide—NFKB1—cardiac atrium—adrenal gland cancer	0.00348	0.0635	CbGeAlD
Thalidomide—NFKB1—pituitary gland—adrenal gland cancer	0.0034	0.0621	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—adrenal gland cancer	0.00313	0.28	CrCbGaD
Thalidomide—NFKB1—adrenal gland—adrenal gland cancer	0.00304	0.0555	CbGeAlD
Thalidomide—CRBN—gonad—adrenal gland cancer	0.00292	0.0533	CbGeAlD
Thalidomide—CRBN—cardiac atrium—adrenal gland cancer	0.00292	0.0533	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—adrenal gland cancer	0.00291	0.26	CrCbGaD
Thalidomide—CRBN—pituitary gland—adrenal gland cancer	0.00285	0.052	CbGeAlD
Thalidomide—Lenalidomide—ABCB1—adrenal gland cancer	0.00266	0.238	CrCbGaD
Thalidomide—CRBN—adrenal gland—adrenal gland cancer	0.00254	0.0465	CbGeAlD
Thalidomide—Pomalidomide—ABCB1—adrenal gland cancer	0.00248	0.221	CrCbGaD
Thalidomide—FGFR2—adrenal gland—adrenal gland cancer	0.00228	0.0416	CbGeAlD
Thalidomide—PTGS2—adrenal cortex—adrenal gland cancer	0.00096	0.0175	CbGeAlD
Thalidomide—CYP1A1—cardiac atrium—adrenal gland cancer	0.000945	0.0173	CbGeAlD
Thalidomide—PTGS1—cardiac atrium—adrenal gland cancer	0.000831	0.0152	CbGeAlD
Thalidomide—PTGS1—pituitary gland—adrenal gland cancer	0.000811	0.0148	CbGeAlD
Thalidomide—PTGS2—pituitary gland—adrenal gland cancer	0.000776	0.0142	CbGeAlD
Thalidomide—CYP2E1—adrenal gland—adrenal gland cancer	0.000752	0.0137	CbGeAlD
Thalidomide—PTGS1—adrenal gland—adrenal gland cancer	0.000725	0.0132	CbGeAlD
Thalidomide—PTGS2—adrenal gland—adrenal gland cancer	0.000693	0.0127	CbGeAlD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	0.000191	0.00109	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GNRHR—adrenal gland cancer	0.000189	0.00108	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.000188	0.00107	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—adrenal gland cancer	0.000187	0.00107	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000185	0.00106	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PRKACA—adrenal gland cancer	0.000185	0.00105	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—adrenal gland cancer	0.000184	0.00105	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—EGFR—adrenal gland cancer	0.000183	0.00104	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—EGFR—adrenal gland cancer	0.000183	0.00104	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—BRAF—adrenal gland cancer	0.000182	0.00104	CbGpPWpGaD
Thalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.00018	0.00103	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—RB1—adrenal gland cancer	0.00018	0.00103	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—adrenal gland cancer	0.000178	0.00101	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—CDKN2A—adrenal gland cancer	0.000176	0.00101	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000176	0.001	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—EGFR—adrenal gland cancer	0.000175	0.001	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—EGFR—adrenal gland cancer	0.000175	0.001	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000174	0.000993	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—POMC—adrenal gland cancer	0.000173	0.000986	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—EGFR—adrenal gland cancer	0.000172	0.000984	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—CTNNB1—adrenal gland cancer	0.000172	0.000982	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CDC42—adrenal gland cancer	0.000172	0.000981	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	0.000171	0.000977	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.000171	0.000976	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—EGFR—adrenal gland cancer	0.00017	0.000967	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—adrenal gland cancer	0.000169	0.000962	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—EGFR—adrenal gland cancer	0.000168	0.000957	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.000167	0.000951	CbGpPWpGaD
Thalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	0.000166	0.000949	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000165	0.000942	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CDC42—adrenal gland cancer	0.000165	0.000942	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—EGFR—adrenal gland cancer	0.000165	0.00094	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—EGFR—adrenal gland cancer	0.000164	0.000935	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—EGFR—adrenal gland cancer	0.000163	0.00093	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CDC42—adrenal gland cancer	0.000163	0.00093	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	0.000163	0.000928	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—EGFR—adrenal gland cancer	0.000162	0.000926	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—EGFR—adrenal gland cancer	0.000161	0.000918	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—adrenal gland cancer	0.00016	0.000913	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CDC42—adrenal gland cancer	0.000157	0.000893	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SDHB—adrenal gland cancer	0.000155	0.000882	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—adrenal gland cancer	0.000153	0.000875	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—EGFR—adrenal gland cancer	0.000153	0.000871	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—EGFR—adrenal gland cancer	0.000153	0.000871	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—EGFR—adrenal gland cancer	0.000153	0.000871	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	0.000151	0.000864	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—EGFR—adrenal gland cancer	0.000151	0.000863	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—EGFR—adrenal gland cancer	0.00015	0.000856	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—EGFR—adrenal gland cancer	0.000149	0.000852	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—EGFR—adrenal gland cancer	0.000149	0.00085	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CDC42—adrenal gland cancer	0.000148	0.000846	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SPRY2—adrenal gland cancer	0.000148	0.000843	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.000146	0.000834	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	0.000146	0.000831	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TP53—adrenal gland cancer	0.000142	0.000812	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—EGFR—adrenal gland cancer	0.000141	0.000806	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—adrenal gland cancer	0.000141	0.000804	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	0.000137	0.000781	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MEN1—adrenal gland cancer	0.000135	0.000773	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—EGFR—adrenal gland cancer	0.000135	0.000772	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.000132	0.000755	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—adrenal gland cancer	0.00013	0.000741	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—POMC—adrenal gland cancer	0.000129	0.000737	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—POMC—adrenal gland cancer	0.000129	0.000735	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—EGFR—adrenal gland cancer	0.000128	0.000729	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	0.000127	0.000725	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—adrenal gland cancer	0.000126	0.000719	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—adrenal gland cancer	0.000126	0.000719	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SH3KBP1—adrenal gland cancer	0.000125	0.000711	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SDHB—adrenal gland cancer	0.000123	0.0007	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—POMC—adrenal gland cancer	0.000122	0.000695	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000122	0.000694	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—BAD—adrenal gland cancer	0.00012	0.000684	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GNRH1—adrenal gland cancer	0.000119	0.000681	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PRKACA—adrenal gland cancer	0.000118	0.000673	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.000117	0.00067	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ZNRF3—adrenal gland cancer	0.000117	0.000668	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SDHB—adrenal gland cancer	0.000115	0.000659	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	0.000115	0.000658	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SDHB—adrenal gland cancer	0.000115	0.000658	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—BAD—adrenal gland cancer	0.000115	0.000657	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—adrenal gland cancer	0.000114	0.000653	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—BAD—adrenal gland cancer	0.000114	0.000649	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GNRH1—adrenal gland cancer	0.000113	0.000646	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PRKACA—adrenal gland cancer	0.000112	0.000639	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—EGFR—adrenal gland cancer	0.00011	0.000625	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—BAD—adrenal gland cancer	0.000109	0.000624	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SPRY2—adrenal gland cancer	0.000109	0.000622	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SDHB—adrenal gland cancer	0.000109	0.000621	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—adrenal gland cancer	0.000107	0.000612	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSHR—adrenal gland cancer	0.000106	0.000607	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—EGFR—adrenal gland cancer	0.000105	0.000598	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—EGFR—adrenal gland cancer	0.000104	0.000593	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SPRY2—adrenal gland cancer	0.000104	0.000591	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PRKACA—adrenal gland cancer	0.000103	0.00059	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSHR—adrenal gland cancer	0.000101	0.000576	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDC42—adrenal gland cancer	0.0001	0.000571	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MEN1—adrenal gland cancer	0.0001	0.00057	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—POMC—adrenal gland cancer	9.97e-05	0.000569	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SDHD—adrenal gland cancer	9.96e-05	0.000568	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—RRM1—adrenal gland cancer	9.96e-05	0.000568	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—adrenal gland cancer	9.81e-05	0.00056	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	9.69e-05	0.000553	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	9.66e-05	0.000551	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	9.61e-05	0.000548	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDC42—adrenal gland cancer	9.5e-05	0.000542	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MEN1—adrenal gland cancer	9.48e-05	0.000541	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—POMC—adrenal gland cancer	9.09e-05	0.000518	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	9.01e-05	0.000514	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CTNNB1—adrenal gland cancer	8.94e-05	0.00051	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SDHB—adrenal gland cancer	8.91e-05	0.000508	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—adrenal gland cancer	8.81e-05	0.000502	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDC42—adrenal gland cancer	8.77e-05	0.0005	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	8.76e-05	0.0005	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	8.57e-05	0.000489	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SDHB—adrenal gland cancer	8.12e-05	0.000464	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—RRM1—adrenal gland cancer	7.91e-05	0.000451	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SDHD—adrenal gland cancer	7.91e-05	0.000451	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CTNNB1—adrenal gland cancer	7.89e-05	0.00045	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—POMC—adrenal gland cancer	7.77e-05	0.000443	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PRKACA—adrenal gland cancer	7.63e-05	0.000435	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	7.49e-05	0.000427	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CTNNB1—adrenal gland cancer	7.49e-05	0.000427	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SDHD—adrenal gland cancer	7.44e-05	0.000425	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—RRM1—adrenal gland cancer	7.44e-05	0.000425	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—RRM1—adrenal gland cancer	7.43e-05	0.000424	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SDHD—adrenal gland cancer	7.43e-05	0.000424	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MED12—adrenal gland cancer	7.43e-05	0.000424	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SPRY2—adrenal gland cancer	7.34e-05	0.000419	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PRKACA—adrenal gland cancer	7.24e-05	0.000413	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	7.13e-05	0.000407	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—adrenal gland cancer	7.08e-05	0.000404	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TERT—adrenal gland cancer	7.04e-05	0.000401	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SDHD—adrenal gland cancer	7.02e-05	0.0004	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—RRM1—adrenal gland cancer	7.02e-05	0.0004	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	7.01e-05	0.0004	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BAD—adrenal gland cancer	6.99e-05	0.000399	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SDHB—adrenal gland cancer	6.94e-05	0.000396	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CTNNB1—adrenal gland cancer	6.81e-05	0.000388	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MEN1—adrenal gland cancer	6.73e-05	0.000384	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	6.64e-05	0.000379	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BAD—adrenal gland cancer	6.63e-05	0.000378	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDC42—adrenal gland cancer	6.47e-05	0.000369	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	6.39e-05	0.000365	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—adrenal gland cancer	6.25e-05	0.000357	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF2—adrenal gland cancer	6.24e-05	0.000356	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GNAS—adrenal gland cancer	6.18e-05	0.000353	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDC42—adrenal gland cancer	6.14e-05	0.00035	CbGpPWpGaD
Thalidomide—FGFR2—Disease—BAD—adrenal gland cancer	6.12e-05	0.000349	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1R—adrenal gland cancer	6.03e-05	0.000344	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—adrenal gland cancer	6e-05	0.000343	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	5.99e-05	0.000342	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—adrenal gland cancer	5.93e-05	0.000338	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF2—adrenal gland cancer	5.92e-05	0.000338	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MED12—adrenal gland cancer	5.89e-05	0.000336	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GNAS—adrenal gland cancer	5.87e-05	0.000335	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SDHD—adrenal gland cancer	5.74e-05	0.000328	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RRM1—adrenal gland cancer	5.74e-05	0.000328	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1R—adrenal gland cancer	5.72e-05	0.000327	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—adrenal gland cancer	5.7e-05	0.000325	CbGpPWpGaD
Thalidomide—FGFR2—Disease—BRAF—adrenal gland cancer	5.57e-05	0.000318	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MED12—adrenal gland cancer	5.55e-05	0.000317	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MED12—adrenal gland cancer	5.54e-05	0.000316	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	5.46e-05	0.000312	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PRKACA—adrenal gland cancer	5.42e-05	0.000309	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—adrenal gland cancer	5.39e-05	0.000308	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	5.29e-05	0.000302	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	5.27e-05	0.000301	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SDHD—adrenal gland cancer	5.24e-05	0.000299	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RRM1—adrenal gland cancer	5.24e-05	0.000299	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MED12—adrenal gland cancer	5.23e-05	0.000298	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TERT—adrenal gland cancer	5.19e-05	0.000296	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRKACA—adrenal gland cancer	5.13e-05	0.000293	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TERT—adrenal gland cancer	4.93e-05	0.000281	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	4.68e-05	0.000267	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTNNB1—adrenal gland cancer	4.6e-05	0.000262	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BAD—adrenal gland cancer	4.52e-05	0.000258	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—adrenal gland cancer	4.5e-05	0.000257	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SDHD—adrenal gland cancer	4.47e-05	0.000255	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RRM1—adrenal gland cancer	4.47e-05	0.000255	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GNAS—adrenal gland cancer	4.39e-05	0.00025	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTNNB1—adrenal gland cancer	4.36e-05	0.000249	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDC42—adrenal gland cancer	4.36e-05	0.000248	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCB1—adrenal gland cancer	4.31e-05	0.000246	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PRKACA—adrenal gland cancer	4.3e-05	0.000245	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BAD—adrenal gland cancer	4.29e-05	0.000245	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MED12—adrenal gland cancer	4.28e-05	0.000244	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—adrenal gland cancer	4.16e-05	0.000238	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BRAF—adrenal gland cancer	4.11e-05	0.000235	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PRKACA—adrenal gland cancer	4.05e-05	0.000231	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PRKACA—adrenal gland cancer	4.04e-05	0.00023	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CTNNB1—adrenal gland cancer	4.03e-05	0.00023	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—adrenal gland cancer	3.95e-05	0.000225	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MED12—adrenal gland cancer	3.9e-05	0.000223	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BRAF—adrenal gland cancer	3.9e-05	0.000223	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	3.83e-05	0.000218	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PRKACA—adrenal gland cancer	3.82e-05	0.000218	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	3.73e-05	0.000213	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—adrenal gland cancer	3.64e-05	0.000208	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TERT—adrenal gland cancer	3.49e-05	0.000199	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	3.49e-05	0.000199	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GNAS—adrenal gland cancer	3.49e-05	0.000199	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—adrenal gland cancer	3.46e-05	0.000197	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCB1—adrenal gland cancer	3.42e-05	0.000195	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MED12—adrenal gland cancer	3.34e-05	0.00019	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GNAS—adrenal gland cancer	3.28e-05	0.000187	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GNAS—adrenal gland cancer	3.27e-05	0.000187	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—adrenal gland cancer	3.22e-05	0.000184	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—adrenal gland cancer	3.21e-05	0.000183	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—adrenal gland cancer	3.19e-05	0.000182	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PRKACA—adrenal gland cancer	3.12e-05	0.000178	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GNAS—adrenal gland cancer	3.09e-05	0.000176	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	3.05e-05	0.000174	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BAD—adrenal gland cancer	3.04e-05	0.000173	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—adrenal gland cancer	3.04e-05	0.000173	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	2.98e-05	0.00017	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—adrenal gland cancer	2.97e-05	0.00017	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—adrenal gland cancer	2.96e-05	0.000169	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PRKACA—adrenal gland cancer	2.85e-05	0.000162	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—adrenal gland cancer	2.82e-05	0.000161	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	2.78e-05	0.000159	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—adrenal gland cancer	2.77e-05	0.000158	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNAS—adrenal gland cancer	2.53e-05	0.000144	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—adrenal gland cancer	2.48e-05	0.000142	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	2.43e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	2.38e-05	0.000136	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—adrenal gland cancer	2.36e-05	0.000135	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—adrenal gland cancer	2.35e-05	0.000134	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—adrenal gland cancer	2.35e-05	0.000134	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNAS—adrenal gland cancer	2.31e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—adrenal gland cancer	2.26e-05	0.000129	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—adrenal gland cancer	2.23e-05	0.000127	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—adrenal gland cancer	2.21e-05	0.000126	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—adrenal gland cancer	2.2e-05	0.000126	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—adrenal gland cancer	2.08e-05	0.000119	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—adrenal gland cancer	2e-05	0.000114	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—adrenal gland cancer	1.98e-05	0.000113	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNAS—adrenal gland cancer	1.97e-05	0.000113	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	1.94e-05	0.00011	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—adrenal gland cancer	1.88e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—adrenal gland cancer	1.76e-05	0.000101	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—adrenal gland cancer	1.76e-05	0.0001	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—adrenal gland cancer	1.7e-05	9.72e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—adrenal gland cancer	1.66e-05	9.48e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—adrenal gland cancer	1.58e-05	9.04e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—adrenal gland cancer	1.55e-05	8.87e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—adrenal gland cancer	1.36e-05	7.76e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—adrenal gland cancer	1.33e-05	7.58e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—adrenal gland cancer	1.24e-05	7.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	1.06e-05	6.04e-05	CbGpPWpGaD
